At this year's Endocrine Society Annual Meeting (#ENDO2026), OrsoBio shared positive Phase 2a results for TLC-2716, our oral, liver-targeted LXR inverse agonist, and the early data are encouraging
"With life expectancy in this country, which is fairly long, we want people to have good coverage for weight loss extending into their senior years," Coviello said
This is a trend weve been seeing and its been seen by other studies as well that theres a shortage of these medications because its a much broader indication now than just diabetics its patients who are obese and dont have diabetes can get these medications, he told us
Luan, S., Cheng, W., Wang, C., Gong, J
Demonstrated this in a 1998 study showing that ipamorelin released GH in a dose-dependent manner in swine without elevating cortisol or prolactin at doses up to 1 mg/kg [1]
The name of the game is no longer only just what your supplement contains, but also how it delivers what it contains